Stifel sees "highly favorable" risk/reward profile for Ocera Therapeutics

|About: Ocera Therapeutics, Inc. (OCRX)|By:, SA News Editor

Shares of Ocera Therapeutics (OCRX +7.7%) have maintained their momentum and are up sharply in afternoon trading.

Details from Stifel's coverage initiation are available.

"We believe the combination of palatable clinical development risk, steady data/news flow, strong patent estate, and potential to meaningfully improve the treatment algorithm in an already greater than $1B HE market opportunity with a rapidly expanding patient demographic creates a highly favorable risk/reward at these levels," analyst Stephen Willey says.